Somnomed Limited (AU:SOM)
ASX:SOM
Want to see AU:SOM full AI Analyst Report?
Top Page
Somnomed Limited
(Sydney:SOM)
Select Model
Select Model
Rating:54Neutral
Price Target:
AU$0.56
▲(0.18% Upside)
Action:Reiterated
Date:04/24/26
The score is driven primarily by mixed financial performance: solid revenue growth and strong cash flow improvement, but persistent losses and negative ROE. The technical setup is weak with the stock below all major moving averages and a negative MACD, while valuation is pressured by a high P/E and no dividend support.
Positive Factors
Revenue Growth
Consistent revenue growth demonstrates expanding demand for SomnoMed’s oral appliance therapy across its markets. Sustained top-line expansion helps absorb fixed manufacturing and R&D costs, supports investment in distribution, and underpins medium-term scale economics if growth persists.
Negative Factors
Operating Profitability Weakness
Persistent negative EBIT and net margins indicate the business has yet to convert healthy gross margins into operating profits. Ongoing SG&A, clinical support or commercialization costs may erode returns, requiring sustained revenue scale or cost control to reach durable profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Consistent revenue growth demonstrates expanding demand for SomnoMed’s oral appliance therapy across its markets. Sustained top-line expansion helps absorb fixed manufacturing and R&D costs, supports investment in distribution, and underpins medium-term scale economics if growth persists.
Read all positive factors
Somnomed Limited (SOM) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$131.45M
Dividend YieldN/A
Average Volume (3M)705.41K
Price to Earnings (P/E)―
Beta (1Y)1.29
Revenue Growth18.21%
EPS Growth65.00%
CountryAU
Employees300
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)N/A
Shares Outstanding219,083,250
10 Day Avg. Volume159,446
30 Day Avg. Volume705,406
Financial Highlights & Ratios
PEG Ratio0.48
Price to Book (P/B)2.97
Price to Sales (P/S)1.24
P/FCF Ratio25.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$1.00Price Target Upside78.57% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Somnomed Limited Business Overview & Revenue Model
Company Description
SomnoMed Limited, together with its subsidiaries, engages in the production and sale of devices for the oral treatment of sleep related disorders in Europe, North America, and the Asia Pacific region. It offers SomnoDent, an oral appliance for obs...
How the Company Makes Money
SomnoMed primarily makes money by selling oral appliance therapy devices (custom-fitted mandibular advancement splints) and associated components that are prescribed for patients with sleep-disordered breathing (notably obstructive sleep apnoea an...
Somnomed Limited Financial Statement Overview
Summary
Income Statement
65
Positive
Balance Sheet
58
Neutral
Cash Flow
70
Positive
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 118.50M | 111.49M | 91.65M | 83.62M | 72.58M | 62.71M |
| Gross Profit | 68.02M | 66.73M | 55.13M | 45.77M | 39.15M | 33.90M |
| EBITDA | 4.18M | 1.58M | -2.33M | 698.39K | 524.53K | 3.57M |
| Net Income | -2.56M | -3.46M | -12.24M | -8.00M | -4.44M | -1.19M |
Balance Sheet | ||||||
| Total Assets | 79.90M | 80.97M | 69.80M | 62.49M | 58.09M | 56.17M |
| Cash, Cash Equivalents and Short-Term Investments | 18.03M | 17.29M | 16.18M | 11.96M | 15.64M | 21.11M |
| Total Debt | 14.01M | 8.03M | 6.72M | 23.51M | 12.01M | 8.91M |
| Total Liabilities | 29.86M | 34.58M | 24.78M | 40.09M | 30.31M | 24.01M |
| Stockholders Equity | 50.04M | 46.39M | 45.02M | 22.40M | 27.79M | 32.16M |
Cash Flow | ||||||
| Free Cash Flow | 3.71M | 5.36M | -7.72M | -10.29M | -6.93M | -1.43M |
| Operating Cash Flow | 7.85M | 7.78M | -6.33M | -3.88M | 1.86M | 2.71M |
| Investing Cash Flow | -5.98M | -3.98M | -5.34M | -6.41M | -8.47M | -4.37M |
| Financing Cash Flow | -1.56M | -3.38M | 16.68M | 6.61M | 2.09M | -6.80M |
Somnomed Limited Technical Analysis
Neutral
0.56
Price Trends
0.59
Positive
0.63
Negative
0.71
Negative
Market Momentum
>-0.01
Negative
58.24
Neutral
91.11
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:SOM, the sentiment is Neutral. The current price of 0.56 is below the 20-day moving average (MA) of 0.57, below the 50-day MA of 0.59, and below the 200-day MA of 0.71, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 58.24 is Neutral, neither overbought nor oversold. The STOCH value of 91.11 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AU:SOM.
Somnomed Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | AU$6.22B | 18.39 | 17.76% | 1.64% | 2.04% | -6.63% | |
54 Neutral | AU$131.45M | -50.85 | -5.31% | ― | 18.21% | 65.00% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | AU$83.20M | -4.02 | -54.48% | ― | 17.24% | -20.00% | |
42 Neutral | AU$52.94M | 467.33 | 0.48% | ― | 24.45% | ― | |
42 Neutral | AU$27.71M | -2.15 | -180.06% | ― | 74.74% | 4.32% | |
41 Neutral | AU$2.26B | -12.24 | -890.76% | ― | -0.80% | -249.48% |
* Healthcare Sector Average
AU:SOM
Somnomed Limited
0.60
-0.02
-3.23%
AU:COH
Cochlear
95.10
-170.84
-64.24%
AU:CMP
Compumedics Limited
0.26
-0.03
-8.93%
AU:CYC
Cyclopharm Limited
0.63
-0.45
-41.67%
AU:MX1
Micro-X Ltd.
0.04
-0.01
-22.00%
AU:4DX
4DMedical Ltd
3.92
3.60
1125.00%
Somnomed Limited Corporate Events
SomnoMed Issues 160,000 Unquoted Options Under Employee Incentive Plan
Mar 20, 2026
SomnoMed Limited has notified the Australian Securities Exchange of the issue of 160,000 unquoted options under its employee incentive scheme. The options, carrying no exercise price and expiring on December 1, 2031, were issued on March 20, 2026 ...
SomnoMed Applies to List 160,000 New Ordinary Shares on ASX
Mar 18, 2026
SomnoMed Limited, an ASX-listed healthcare company focused on sleep-related medical solutions, continues to build its presence in the medical technology market with products aimed at patients and clinicians managing sleep disorders.The company has...
SomnoMed Seeks ASX Quotation for 480,000 New Ordinary Shares
Mar 9, 2026
SomnoMed Limited has applied to the ASX for quotation of 480,000 new ordinary fully paid shares, with an issue date of March 9, 2026. The application indicates these additional securities stem from the exercise or conversion of existing options or...
SomnoMed Options Lapse, Trimming Future Equity Overhang
Mar 9, 2026
SomnoMed Limited has notified the market of the cessation of 171,000 SOMAA options, which were due to expire on 24 June 2027 with an exercise price of $2.00. The options have lapsed because the conditions attached to these rights were not met or h...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.